EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

COMPARATIVE STUDY BETWEEN PEG-IFN BASED REGIMEN (PEG-IFN / SOFOSBUVIR / RIBAVIRIN) AND PEG-IFN FREE REGIMENS (SOFOSBUVIR / SIMEPREVIR) - (SOFOSBUVIR / RIBAVIRIN) IN EGYPTIAN PATIENTS WITH CHRONIC HCV INFECTION.

Mahmoud Ezzat Elmashad*, Assem Mahmoud Elsherif, Magdy Abdelkarim Eldahshan,
Mohammed Salah Ali and Abdelhalim Assem Mahmoud

ABSTRACT

Annually about 150 million people worldwide have chronic hepatitis C viral (HCV) infection. Advances in the molecular biology of the HCV replication life cycle have led to the discovery of several molecules that specifically block various viral proteins and globally called direct-acting antiviral (DAA) agents. We aimed to evaluate of the efficacy and safety of Peg-IFN based triple regimen (Peg-IFN / Sofosbuvir / Ribavirin) versus Peg-IFN free regimens including (Sofosbuvir/Simeprevir) and (Sofosbuvir/Ribavirin) in adult Egyptian patients with chronic HCV genotype 4. We prospectively enrolled 920 patients from Internal Medicine Departments of Ahmed Maher and Al-Hussein University hospitals, Cairo, Egypt, only one hundred and fifty (150) adult patients with chronic hepatitis C virus infection were included in the study. Patients were divided into 3 groups treated with Pegylated interferon plus Sofosbuvir plus Ribavirin (group A), Sofosbuvir plus Simeprevir (group B) and Sofosbuvir plus Ribavirin (group C) respectively. In group A, the percent of patients who achieved SVR12 were 86.5% for naïve, 81.5% for experienced and 84% for the all (naïve and experienced). In group B, the percent of patients who achieved SVR12 were 94% for naïve, 90% for experienced and 92% for the all (naïve and experienced). In group C, the SVR12 rates were 84% for naïve, 72% for experienced and 78% for the all (naïve and experienced). In conclusion, the sustained virological response 12 weeks after treatment among the three studied groups are nearly the same with no statistically significant difference but only group B (Sofosbuvir plus Simeprevir) regimen gave good results with shorter duration and less adverse events compared with other regimens.

Keywords: HCV, Hepatitis C Virus; DAAs: Direct Anti-Viral Agents.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 March 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: MARCH ISSUE PUBLISHED

    MARCH 2024 issue has been successfully launched on MARCH 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia